EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC

Allison E B Chang iD, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky iD, Julia Rotow, Pasi A Jänne, Mari Mino-Kenudson, Scott Swanson, Cameron D Wright, David Kozono, Paul Marcoux und 3 weitere

The Oncologist · 05.07.2024 · 29 (7) · 609-618

DOI: 10.1093/oncolo/oyae107 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 18.05.2024. Verfasst von Allison E B Chang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Afatinib, Lung Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non–small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with concurrent chemoradiotherapy (cCRT) in locally advanced disease. The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and cCRT with or without surgery in locally advanced epidermal growth factor receptor (EGFR)-mutant NSCLC. Patients and Methods Adults ≥18 years with histologically confirmed stage III (AJCC 7th edition) NSCLC with activating EGFR mutations were enrolled at Mass General and Dana-Farber/Brigham Cancer Centers, Boston, Massachusetts. Patients received induction afatinib 40 mg daily for 2 months, then cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 IV every 3 weeks during RT (definitive or neoadjuvant dosing). Patients with resectable disease underwent surgery. All patients were offered consolidation afatinib for 2 years. The primary endpoint was the objective response rate (ORR) to induction TKI. Secondary endpoints were safety, conversion to operability, progression-free survival (PFS), and overall survival (OS). Analyses were performed on the intention-to-treat population.

Results

Nineteen patients (median age 56 years; 74% female) were enrolled. ORR to induction afatinib was 63%. Seventeen patients received cCRT; 2/9 previously unresectable became resectable. Ten underwent surgery; 6 had a major or complete pathological response. Thirteen received consolidation afatinib. With a median follow-up of 5.0 years, median PFS and OS were 2.6 (95% CI, 1.4-3.1) and 5.8 years (2.9-NR), respectively. Sixteen recurred or died; 6 recurrences were isolated to CNS. The median time to progression after stopping consolidation TKI was 2.9 months (95% CI, 1.1-7.2). Four developed grade 2 pneumonitis. There were no treatment-related deaths.

Conclusion

We explored the efficacy of combining TKI with cCRT in oncogene-driven NSCLC. Induction TKI did not compromise subsequent receipt of multimodality therapy. PFS was promising, but the prevalence of CNS-only recurrences and rapid progression after TKI discontinuation speak to unmet needs in measuring and eradicating micrometastatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAfatinibLung NeoplasmsErbB ReceptorsChemoradiotherapyHumansFemaleMaleMiddle AgedAgedMutationAdultNeoplasm StagingAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

EGFR-mutantlung canceroncogenesradiation oncologystage IIIsurgical oncology

Substanzen

AfatinibErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, United States.
  • Department of Medicine, Division of Hematology/Oncology, Lahey Hospital and Medical Center, Burlington, MA 01805, United States.
  • Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02215, United States.
  • Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA 02114, United States.
  • Massachusetts General Hospital Biostatistics Center, Boston, MA 02114, United States.
  • Lowe Center for Thoracic Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, United States.

ORCID-Profile: Allison E B Chang, Alona Muzikansky

Zitieren

APA

Chang, A. E. B., Piper-Vallillo, A. J., Mak, R. H., Lanuti, M., Muzikansky, A., Rotow, J., Jänne, P. A., Mino-Kenudson, M., Swanson, S., Wright, C. D., Kozono, D., Marcoux, P., Piotrowska, Z., Sequist, L. V., & Willers, H. (2024). The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. The Oncologist, 29(7), 609-618. https://doi.org/10.1093/oncolo/oyae107

Vancouver

Chang AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, Muzikansky A, Rotow J, et al. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. The Oncologist. 2024;29(7):609-618. doi:10.1093/oncolo/oyae107

BibTeX
@article{Chang2024,
  author = {Chang, Allison E B and Piper-Vallillo, Andrew J and Mak, Raymond H and Lanuti, Michael and Muzikansky, Alona and Rotow, Julia and Jänne, Pasi A and Mino-Kenudson, Mari and Swanson, Scott and Wright, Cameron D and Kozono, David and Marcoux, Paul and Piotrowska, Zofia and Sequist, Lecia V and Willers, Henning},
  title = {The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {7},
  pages = {609--618},
  doi = {10.1093/oncolo/oyae107}
}
Kostenlos starten →